Skip to main content
Equibles
CBDY logo

CBDY · Target Group Inc. · Metrics

Track CBDY — free

Use CBDY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CBDY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+0.00%) At close · Oct 21
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The unaudited accompanying condensed consolidated interim financial statements have been prepared assuming that the Company will continue as a going concern up to at least 12 months from the balance sheet date; however, the above condition raises substantial doubt about the Company's ability to do so.”
View the 10-Q filed Aug 13, 2026
Market Cap
$617,026
Shares
617.03M
Volume · Oct 21 500K Avg daily vol (33 sessions) 373.06K

CBDY metrics

60 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$617,026

Price action

20 metrics
Price change (1W)
+42.9%
Price change (30D)
+25.0%
Price change (3M)
-16.7%
Price change (6M)
-41.2%
Price change (YTD)
-33.3%
Price change (1Y)
-33.3%
Trailing year
Price change (5Y)
-93.5%
52-week high
$0.00
52-week low
$0.00
Change from 52-week high
-66.7%
Change from 52-week low
+100.0%
Annualized volatility
343.8%
Annualized volatility (3M)
—
Beta
-1.2
RSI (14D)
53.5
Price vs SMA 50
+1.2%
Price vs SMA 200
-33.4%
Avg volume (3M)
373,062
Relative volume
1.3
Average dollar volume
$291

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
617.03M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.3×
reciprocal yield 44.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.2×
reciprocal yield 566.4%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-295.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.6×
reciprocal yield 61.4%
EV / revenue historical average (5Y)
1.6×
reciprocal yield 61.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
39.2%
Operating margin
—
Trailing 12 months
Net margin
-52.1%
Gross profit (TTM)
$1.37M
Operating profit (TTM)
—
Net income (TTM)
−$1.82M
Trailing 12 months
Diluted EPS (TTM)
$0.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.01
Gross profit per diluted share (TTM)
$0.00
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$0.00
Operating cash flow per diluted share (TTM)
$0.00
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.01

Growth

11 metrics
Revenue growth YoY
+10.8%
Year over year
Net income growth YoY
-947.1%
Revenue (TTM)
$3.50M
Trailing 12 months
EPS growth YoY
-1,200.0%
Shares change YoY
+0.0%
Year over year
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
+164.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-32.1%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$7.32M
Latest balance sheet
Cash & equivalents
$14,006
Total assets
$5.68M
Total debt
$7.33M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.07M
Capital expenditures (TTM)
$3,799
R&D (TTM)
$0
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
33 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1586554 Visit website Investor relations